Volociximab-ranibizumab combination therapy for AMD
Volociximab, an alpha-5 beta-1 integrin antagonist, combined with Lucentis treatments for wet AMD is showing a favorable safety profile in early phase 1 studies, according to a poster presentation at the 2009 ARVO meeting. Baruch D. Kupperman reported on completed dose escalation results for 10 subjects enrolled in the study. Patients received three monthly intravitreal injections of volociximab in treatment-naive eyes at one of three doses in combination with Lucentis. "Dose escalation was completed without evidence of dose-limiting toxicity or drug-related adverse events," Dr. Kupperman said. "Results to date... suggest that volociximab has a favorable safety profile," he said.